Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson#s Disease (PD) Patients Whose Symptoms are Uncontrolled With Oral Medication

Food and Healthcare Press Releases Monday August 6, 2018 11:25
LONDON--6 Aug--PRNewswire/InfoQuest
Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].

Treatment with APO-go(R)/MOVAPO(R) (apomorphine) subcutaneous infusion for 12 weeks gave significantly greater reductions in OFF time (periods when PD medications don't work) from baseline compared with placebo: -2.47 h/day versus -0.58 h/day, respectively - a treatment difference of almost 2 hours (p=0.0025) and double the change in OFF time recognised as meaningful to PD patients. These reductions were seen in the first week of treatment with APO-go(R)/MOVAPO(R) infusion.

Compared with placebo, significantly greater increases in ON time (periods with good motor control) without troublesome dyskinesia - 'good' ON time - from baseline were observed with APO-go(R)/MOVAPO(R) infusion: 2-77 h/day versus 0-80 h/day, respectively (p=0-0008), and patients could also reduce the dosage and number of administrations of concomitant oral PD medications significantly (p=0.0014).

APO-go(R)/MOVAPO[(R)/] infusion is an established therapy for PD, a disease characterised by progressive degeneration of dopamine-containing neurons in the brain, resulting in loss of motor control. TOLEDO is the first multicentre, randomised, double-blind trial to investigate its efficacy and safety in PD and was undertaken in 107 patients from 23 hospitals in 7 countries whose symptoms were uncontrolled despite taking multiple medications.

Clinical improvements were reflected in patients' assessment of treatment: significantly more APO-go(R)/ MOVAPO(R) infusion patients rated themselves as 'improved' (71%) versus placebo (18%; p<0.0001).
Professor Regina Katzenschlager, lead investigator of TOLEDO, commented:

"TOLEDO is an important addition to our knowledge, providing Level 1 evidence for the first time and confirming previous observational studies. Apomorphine infusion is effective and well tolerated by patients experiencing debilitating treatment response fluctuations despite optimised treatment."

Professor Andrew Lees, an investigator in the pivotal clinical trial that led to apomorphine being licensed for PD treatment in the UK, added:
"We hope the positive results of the TOLEDO study will help ensure apomorphine infusion, which is delivered using a small, ambulatory mini-pump, is incorporated into national PD treatment guidelines."
The TOLEDO study is sponsored by Britannia Pharmaceuticals Ltd., part of the STADA Arzneimittel AG group of companies and manufacturer of apomorphine products.
Founded in 1982, Britannia Pharmaceuticals Limited is a pharmaceutical company based in Reading, UK, specialising in the neurology market.
Britannia is owned by Frankfurt-based STADA Arzneimittel AG.

APO-go(R) products are marketed in the UK by Britannia Pharmaceuticals Ltd and transferred with the acquisition of Britannia into the STADA portfolio in 2007. APO-go(R) products are marketed outside the UK through own affiliates and licensing partners.

For information about:
Britannia Pharmaceuticals Ltd:
http://www.britannia-pharm.com
TOLEDO study:
https://www.clinicaltrials.gov/ct2/show/NCT02006121?term=NCT02006121&rank=1
For the APO-go(R) infusion SmPC:
https://www.medicines.org.uk/emc/product/3908/smpc
[1]Katzenschlager R, et al. Lancet Neurology, 2018. Published online July 25, 2018   http://dx.doi.org/10.1016/S1474-4422(18)30239-4
Source: Britannia Pharmaceuticals Ltd

Latest Press Release

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

SI Group Announces New Executive Leadership

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals and chemical intermediates, announced today the company's new executive leadership team. These changes follow the October 15, 2018...

Grunenthal Acquires Global Rights for Qutenza(R)

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now...

Related Topics